Clorox (CLX) is likely to post a soft fiscal Q1 as enterprise resource planning-related disruptions and weak demand weigh on sales, UBS Securities said in a note emailed Monday.

UBS expects fiscal Q1 organic sales decline of more than 19%, and earnings per share of $0.82. The firm said investors are debating whether management may trim fiscal 2026 guidance, though current targets still appear achievable at the lower end, according to the note.

Clorox will release its fiscal Q1 results on Nov. 3.

UBS said Clorox's stock underperformance and current valuation suggest much of the near-term weakness is already reflected in prices. It maintains a neutral rating with a $128 price target.

Price: 115.20, Change: -0.65, Percent Change: -0.56